Navigation Links
Cystic Fibrosis Foundation funds Marshall research
Date:3/28/2011

HUNTINGTON, W.Va. The Cystic Fibrosis Foundation has awarded a Marshall University scientist a two-year, $194,400 grant.

The grant to Dr. Hongwei Yu, professor in the Department of Biochemistry and Microbiology at the university's Joan C. Edwards School of Medicine, will help further his lab's work to explore the factors that control the overproduction of mucus in the lungs of cystic fibrosis (CF) patients.

According to Yu, chronic bronchial pneumonia caused by the bacterium Pseudomonas aeruginosa is a life-threatening condition for patients with CF.

"During these infections in CF patients, the bacterium is capable of producing copious amounts of alginatea thick, sugar-like polymer that plugs the airways, making breathing difficult," he said. "The alginate also helps form a thick, slimy 'biofilm' around the colonies of bacteria, protecting them from the body's immune defense mechanisms and making antibiotic treatment less effective."

Yu said the long-range goal of his research is to better understand the mechanisms of how this bacterium regulates production of the alginate biofilms in order to develop a more effective treatment option to inhibit or suppress the formation of alginate biofilms in the lungs of CF patients.

"For this project, we will be accessing the relevance of two newly identified proteins that act as alginate regulators. Once the mechanisms controlling alginate production are fully understood, it may be possible to improve treatment of these bacterial infections in CF patients by modulating or suppressing that production," he added.

Dr. John Maher, Marshall's vice president for research, congratulated Yu and praised him and his team for obtaining the grant.

"Dr. Yu's work is an excellent example of the vital research here at Marshall University that can affect the health and welfare of people everywhere. Research in his lab has the potential to have a real impact on the quality of life for people with cystic fibrosis," said Maher.

Maher also noted that Yu's research has had a regional economic development impact, saying his work has led to a patent and the development of Progenesis Technologies LLC, a West Virginia-based biotech research and development company. A second patent is pending.


'/>"/>

Contact: Ginny Painter
ginny.painter@marshall.edu
30-474-611-964
Marshall University Research Corporation
Source:Eurekalert  

Related biology news :

1. Pig model of cystic fibrosis improves understanding of disease
2. Breakthrough on cystic fibrosis 1 step closer as new research alliance formed
3. Women with polycystic ovary syndrome may be more vulnerable to BPA
4. Common diabetes drug may halt growth of cysts in polycystic kidney disease
5. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
6. Drug may treat cystic fibrosis, other diseases caused by nonsense mutations, UAB researcher says
7. Research project yields better understanding of the defective protein that causes cystic fibrosis
8. Cystic fibrosis testing -- next steps
9. Two-pronged model could help foil tough cystic fibrosis infections
10. Nanoemulsion potent against superbugs that kill cystic fibrosis patients
11. New test promises quicker, more accurate evaluation for cystic fibrosis patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cystic Fibrosis Foundation funds Marshall research
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)...  ArmaGen, Inc., today announced that it has ... executive officer, as well as a member of ... more than 17 years of executive management experience ... and pharmaceuticals. "Mathias is a ... skillset necessary to lead ArmaGen to its next ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... of drug and device development, and Prism Clinical Research , a leader ... announced Verified Clinical Trials (VCT) has been selected by both companies ...
Breaking Biology Technology: